We assessed characteristics associated with all-cause mortality among US patients with multidrug-resistant tuberculosis. Mortality decreased from 31% during 1993-2002 to 11% during 2003-2013. Directly observed therapy coverage increased from 74% to 95% and was protective against all-cause mortality after accounting for demographics, clinical characteristics, human immunodeficiency virus status, and period of treatment.
Multidrug-resistant (MDR) tuberculosis (TB) is diagnosed when a patient's Mycobacterium tuberculosis isolate shows resistance to isoniazid and rifampin. Globally, approximately 3.3% of new cases and 20% of previously treated cases have MDR-TB [1] , whereas in the United States, MDR-TB represents 1% of new cases and 7% of previously treated cases [2] . Because MDR-TB treatment regimens are less effective and more complex than regimens for drug-sensitive TB, patients with MDR-TB are at higher risk of poor outcomes and death [3, 4] . Patients may benefit the most from patient-centered interventions such as directly observed therapy (DOT), which is an intervention to increase treatment adherence and generally considered to improve TB treatment outcomes. However, few studies have assessed the effects of DOT among MDR-TB patients in the United States [5] .
We describe the characteristics of US patients treated for MDR-TB and assess whether DOT was associated with lower rates of all-cause mortality during TB treatment.
METHODS
We analyzed data for US TB cases reported during 1993-2013 to the National Tuberculosis Surveillance System (NTSS) at the Centers for Disease Control and Prevention. In brief, health departments in the 50 states and the District of Columbia electronically report verified TB cases that meet a nationally standardized case definition. Reports include patient demographic information, medical and social risk factors for TB, and clinical, treatment, and outcome information about the case (treatment completion, death, loss to follow-up, treatment refusal, adverse event, other) [2] . The study outcome was all-cause mortality during TB treatment as reported in NTSS through 2013, the most recent year for which outcome data were available in NTSS. We excluded patients who (i) had non-MDR-TB; (ii) were dead at the time of diagnosis; (iii) had missing, or implausible, time-to-event data; or (iv) lacked outcome data (Supplementary Data 1) .
We examined age, sex, patient's origin (US-born or foreign-born), and self-identified race/ethnicity. Any substance use (alcohol use, injection drug use, or noninjection drug use), homelessness, and diagnosis of TB in a correctional facility were recorded for the year before TB diagnosis. Anatomic disease site (only pulmonary or any extrapulmonary disease), sputum smear positivity for acid-fast bacilli, cavitary disease, previous TB, and human immunodeficiency virus (HIV) status were recorded at the time of diagnosis. Initial TB drug susceptibility testing results were classified as plain MDR-TB (resistance to isoniazid and rifampin, but not to a fluoroquinolone or to a second-line injectable drug) or MDR-TB with additional drug resistance (resistance to isoniazid and rifampin with additional resistance to at least a fluoroquinolone or a second-line injectable). Treatment administration mode was classified as any DOT or all self-administered therapy.
We used Cox proportional hazards models of duration of TB treatment (ie, time from TB treatment start until treatment was completed, treatment stopped, or the patient died) to estimate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). We censored patients who stopped therapy before completion for any reason listed in the surveillance form other than death (eg, lost to follow-up). Age (in 5-year increments), sex, race/ethnicity, substance use, homelessness, incarceration, disease site, previous TB, HIV infection, resistance pattern, and treatment administration mode were included a priori in multivariable analyses, regardless of univariable estimates. Because the epidemiology of TB in the United States varies by patient origin, we stratified our models by US-born or foreign-born. Additionally, we further stratified our dataset into 2 intervals for the 1993-2002 and 2003-2013 treatment periods because DOT practices, the availability and effectiveness of antiretroviral therapy for HIV, and TB diagnostics and treatments improved substantially during these periods. All analyses were performed using Stata statistical software (StataCorp, College Station, Texas), version 14.0. All data were collected and analyzed as part of routine public health surveillance, which did not require institutional review board approval.
RESULTS
A total of 3434 MDR-TB cases reported to NTSS during 1993-2013 was included in the study ( 
in all stratified models after accounting for numerous characteristics, including social risk factors.
DISCUSSION
In the United States, all-cause mortality among patients with MDR-TB decreased substantially between 1993-2002 and 2003-2013, possibly due to improved detection and treatment, advances in HIV care, and expansion of DOT coverage. In our analysis, HIV infection remained a risk factor for death; its effect was higher among the foreign-born, after controlling for known mortality risk factors. DOT was protective irrespective of treatment period or patient's origin. Among US-born patients, mortality was associated with Hispanic ethnicity and male sex.
HIV infection was considered one of the main drivers of the TB resurgence in the 1980s and 1990s in the United States, when MDR-TB outbreaks were reported in large urban centers among people living with HIV [6] . In the late 1990s, combination antiretroviral therapy became available, dramatically improving the prognosis of HIV infection in the United States [7] . In this investigation, we found that the effect of HIV on mortality greatly decreased from 1993-2002 to 2003-2013. However, these estimates were imprecise due to missing data on HIV infection. Because we used routinely reported TB surveillance data, detailed HIV care metrics such as CD4 counts or antiretroviral regimen characteristics were unavailable, precluding our ability to assess the effects of HIV care. Even after accounting for treatment period, foreign-born people living with both HIV and MDR-TB had nearly twice the risk of death as their US-born counterparts. Foreign-born people living with HIV in the United States may have similar rates of viral suppression to those of US-born individuals [8] , but there are no published data on rates of viral suppression and their effects on outcomes among people living with both HIV and TB in the United States that could shed light on the disparity of outcomes presented here. Ensuring treatment adherence was recognized as key to treatment success early in the history of TB pharmacologic treatment [9] . In the 1990s, measures to increase adherence such as DOT expanded in the United States and played a role in the successful national TB rate reduction during 1993-2013 [10] . However, randomized clinical trials have not always shown a beneficial effect of DOT on TB treatment outcomes. In a meta-analysis of 6 trials for non-MDR-TB [11] , 2 studies showed better outcomes among patients receiving DOT. The authors of those 2 studies noted that the comparison group (self-administered therapy) received only monthly clinic visits and postulated that weekly or biweekly clinic visits might be equivalent to DOT as a strategy to improve outcomes. In the United States, DOT is usually provided by local health departments, where other patient-centered measures to improve adherence (incentives and enablers) are also implemented [12] . Therefore, our surveillance variable of DOT may be a proxy for additional patient-centered factors that benefit MDR-TB patients' treatment and care. However, data on other measures complementary to DOT to improve patient outcomes, as well as reasons for offering self-administered therapy to patients with MDR-TB, were not recorded in NTSS.
In conclusion, all-cause mortality among MDR-TB patients has decreased significantly over time in the United States. However, foreign-born patients living with HIV infection still have twice the risk of death compared with US-born MDR-TB patients living with HIV infection. DOT was protective against all-cause mortality irrespective of treatment period or patient's origin.
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